Top 10 Multinational Pharmaceutical Companies by 2024 Revenue: Johnson & Johnson, Roche, Merck & Co. and Others File Prospectus

　　【Pharmaceutical Network Industry Dynamics】As of now, the financial reports of multinational pharmaceutical companies have been released one after another. The top 10 companies by revenue are Johnson & Johnson, Roche, Merck, Pfizer, AbbVie, AstraZeneca, Novartis, Bristol-Myers Squibb, Eli Lilly, and Sanofi.
 

Among them, Johnson & Johnson remains firmly in the top position in terms of revenue, with a total revenue of $88.8 billion in 2024, representing a year-on-year increase of 4.3%. Oncology is the core driver of Johnson & Johnson's performance, with this segment generating a full-year revenue of $17.828 billion, representing a year-on-year decrease of 1.2%.
 

Roche achieved revenue of 60.495 billion Swiss francs (approximately 66.9 billion US dollars) in 2024, representing a year-on-year increase of 7%. The company has a total of 17 drugs with annual sales exceeding 1 billion US dollars: the ophthalmology bispecific antibody drug Faricimab (Vabysmo) showed strong growth, with its sales increasing by 68% over the previous year; followed by the subcutaneous injection Pertuzumab and Trastuzumab combination Phesgo, which achieved a 62% increase in sales for the whole of last year.
 

Merck's Total Revenue for the Full Year 2024 Reached $64.168 Billion, a 7% Increase Year-over-Year
 

Pfizer Achieves $17.763 Billion in Q4 Revenue, Up 21% Year-over-Year; Full-Year Revenue Reaches $63.627 Billion, Up 7% Year-over-Year. For its 2025 outlook, Pfizer projects total sales between $61 billion and $64 billion.
 

AbbVie's total revenue for the full year 2024 was $56.334 billion, a year-on-year increase of 3.7%. Among this, the autoimmune business contributed $26.682 billion in revenue to the company, a year-on-year increase of 2.1%; the oncology and neuroscience businesses achieved sales growth of 10.8% and 16.6%, respectively, reaching $6.555 billion and $8.999 billion; the aesthetics and ophthalmology businesses slightly declined, with full-year sales of $5.176 billion and $2.242 billion, respectively.
 

AstraZeneca's total revenue for the full year 2024 reached $54.073 billion, a year-on-year increase of 21%. The oncology business performed strongly, generating revenue of $22.353 billion, a year-on-year increase of 24%, accounting for 41% of total revenue; the respiratory and immunology business achieved annual sales growth of 25% to $7.876 billion. The other three major business segments: vaccines and immunity, rare diseases, cardiovascular, renal, and metabolic diseases, realized revenues of $1.462 billion, $8.768 billion, and $12.517 billion respectively in 2024; representing year-on-year growth of 8%, 16%, and 20% respectively.
 

Novartis' total revenue for the full year 2024 reached $50.317 billion, representing a 12% year-on-year increase. Of this, revenue from the Chinese market amounted to $3.9 billion, marking a 21% year-on-year growth. The four major therapeutic areas — Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, and Oncology — generated revenues of $8.576 billion, $9.293 billion, $4.750 billion, and $14.740 billion respectively, with year-on-year growth rates of 36%, 21%, 31%, and 16% respectively.
 

Bristol-Myers Squibb Achieves $48.3 Billion in Revenue in 2024, a 7% Increase Year-over-Year
 

Eli Lilly's 2024 financial report shows that the company's total revenue for the previous year was $45.043 billion, a year-on-year increase of 32%; net profit was $10.59 billion, a year-on-year increase of 106%. Among this, the combined sales of tirzepatide (including the weight loss version and the blood sugar reduction version) reached $16.466 billion, accounting for more than 36% of total revenue.
 

In 2024, Sanofi achieved a total annual revenue of 41.081 billion euros (approximately 43.028 billion US dollars), representing a year-on-year increase of 11.3%. Among this, immunology remains Sanofi's advantageous business segment, with last year’s total revenue reaching 13.496 billion euros (approximately 14.136 billion US dollars); the vaccine segment generated a revenue of 8.298 billion euros (8.691 billion US dollars); the four major business segments of rare diseases, neurology, oncology, and others respectively achieved revenues of 5.9 billion euros (6.183 billion US dollars), 379 million euros (397 million US dollars), 944 million euros (989 million US dollars), and 12.063 billion euros (12.642 billion US dollars).
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.